Cleveland Clinic empowers caregivers to minimize the impacts of healthcare while optimizing patient outcomes and supporting the community. The Department of Pharmacy has a \"Greening the Pharmacy\" initiative with the goal of leading by example and acting as stewards of our natural resources for the wellbeing of all.
Physical Requirements:
Typical physical demands include ability to perform the job while standing, walking, reaching, stretching and sitting for prolonged periods; manual dexterity sufficient to perform computer, dispensing, and compounding.
Personal Protective Equipment:
Follows standard precautions using personal protective equipment as required.
The policy of Cleveland Clinic Health System and its system hospitals (Cleveland Clinic Health System) is to provide equal opportunity to all of our caregivers and applicants for employment in our tobacco free and drug free environment. All offers of employment are followed by testing for controlled substance and nicotine. All offers of employment are follwed by testing for controlled substances and nicotine. All new caregivers must clear a nicotine test within their 90-day new hire period. Candidates for employment who are impacted by Cleveland Clinic Health System's Smoking Policy will be permitted to reapply for open positions after one year.
Cleveland Clinic Health System administers an influenza prevention program. You will be required to comply with this program, which will include obtaining an influenza vaccination on an annual basis or obtaining an approved exemption.
Decisions concerning employment, transfers and promotions are made upon the basis of the best qualified candidate without regard to color, race, religion, national origin, age, sex, sexual orientation, marital status, ancestry, status as a disabled or Vietnam era veteran or any other characteristic protected by law. Information provided on this application may be shared with any Cleveland Clinic Health System facility.
Please review the Equal Employment Opportunity poster.
Cleveland Clinic Health System is pleased to be an equal employment employer: Women / Minorities / Veterans / Individuals with Disabilities
","datePosted":"2025-04-12T11:41","employmentType":"FULL_TIME","jobLocation":[{"@type":"Place","address":{"@type":"PostalAddress","addressLocality":"Cleveland, OH, USA","addressRegion":null,"addressCountry":"United States"}}],"directApply":false,"hiringOrganization":{"@type":"Organization","name":"Cleveland Clinic","sameAs":"https://my.clevelandclinic.org/","logo":"https://storage.googleapis.com/simplify-imgs/companies/5b733983-1faf-476a-bebb-6b391785fa6b/logo.png"},"identifier":{"@type":"PropertyValue","name":"Cleveland Clinic","value":"5b733983-1faf-476a-bebb-6b391785fa6b"}}Full-Time
Non-profit academic medical center providing healthcare
No salary listed
Entry, Junior
Company Does Not Provide H1B Sponsorship
Cleveland, OH, USA
Upload your resume to see how it matches keywords from the job description.
Cleveland Clinic is a non-profit academic medical center that provides high-quality clinical and hospital care, including routine check-ups, specialized treatments, and life-saving surgeries. It offers virtual visits and second opinions to improve accessibility and operates multiple locations in Ohio, Florida, Abu Dhabi, and Canada. The clinic generates revenue primarily through patient services and enhances the patient experience with resources like MyChart for health record management. Cleveland Clinic aims to deliver exceptional medical care, advance medical research, and educate future healthcare professionals.
Company Size
N/A
Company Stage
Grant
Total Funding
$74.7M
Headquarters
Cleveland, Ohio
Founded
1921
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Professional Development Budget
Mental Health Support
Dyania Health, an AI-powered healthcare data company, today announced the close of its $10 million Series A funding round led by Health..
Omega Funds and Intuitive Ventures join top-tier syndicate of healthcare investors to support ongoing clinical activitiesUNION CITY, Calif., Aug. 21, 2024 /PRNewswire/ -- XII Medical, Inc., a clinical-stage medical technology company developing innovative therapies for obstructive sleep apnea, today announced the closing of a $45 million Series B equity financing. The financing was led by Omega Funds and joined by new investor Intuitive Ventures. Existing investors also participated, including founding investor Cleveland Clinic, Ajax Health, Longview Ventures (an affiliate of Broadview Ventures), Aperture Venture Partners, JobsOhio Growth Capital Fund and an undisclosed strategic investor. Funds will be utilized to further product and clinical development. XII Medical has developed a state-of-the-art, patient-centric neuromodulation therapy designed to enhance quality of life for the millions of people suffering from obstructive sleep apnea.Obstructive sleep apnea (OSA) is a disorder in which the muscles in the throat temporarily relax, causing blockage of the airway during sleep
NeuroTherapia, a Cleveland, OH-based clinical-stage company focused on developing therapies for neurodegenerative diseases, raised $12.3M in Series B funding.The round was led by Cleveland Clinic, and included all previous investors, Brain Trust Accelerator Fund II, Dolby Family Ventures and the Alzheimer’s Drug Discovery Foundation (ADDF) as well as new investors, Foundation for a Better World and CRUINT. Led by President and CEO Tony Giordano, NeuroTherapia is a clinical-stage biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous system (CNS), including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other CNS conditions. NeuroTherapia is developing therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation in the CNS, without affecting the clearance of toxic beta amyloid.The company intends to use the funds for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer’s disease (AD). NeuroTherapia will continue to raise additional funds for its second close in six months, which will enable development of a recently discovered second generation molecule for a separate indication in which neuroinflammation plays a major role.FinSMEs06/08/2024
/PRNewswire/ -- Enspire DBS Therapy, Inc., (Enspire) a clinical stage company developing an implantable neuromodulation therapy for post-stroke recovery,...